Breast Cancer Therapy
Research in the area of breast cancer therapy reported from Novartis
Published in Women's Health Weekly, April 12th, 2007
Fresh data on breast cancer are presented in the report "Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Adjuvant tamoxifen therapy for 5 years reduces recurrence in hormone receptor positive, post-menopausal women with early breast cancer, but offers no advantage when prolonged to another 5 years, during which the risk of recurrence remains high. Treating patients, who remain disease-free after 5 years of tamoxifen, with letrozole significantly reduces recurrence, regardless of nodal status," scientists writing in the journal Breast Cancer Research and Treatment report.
"This study evaluated the life-time...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Arthritis
Women who keep moving dodge arthritis pain - Breast Cancer
Few surgeons routinely refer breast cancer patients for reconstruction, U-M study finds - Breast Cancer
Lack of care reported for older breast cancer patients - Breast Cancer
MRI screening of opposite breast necessary for women with recent breast cancer diagnosis - HIV/AIDS
Community-based measures fail to reduce HIV levels, new study shows - Hypertension
New survey evidence on the health and well-being of England's older generation - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
